Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Biosyent Inc V.RX

Alternate Symbol(s):  BIOYF

BioSyent Inc. is a specialty pharmaceutical company. The Company, through its wholly owned subsidiaries, BioSyent Pharma Inc., and BioSyent Pharma International Inc., acquires or licenses and develops pharmaceutical and other healthcare products for sale in Canada and certain international markets. Hedley Technologies Ltd., a wholly owned subsidiary operates the Company’s business marketing biologically and health friendly non-chemical insecticides. Its products include Combogesic, Cathejell, FeraMAX Pd Therapeutic 150, FeraMAX Pd Maintenance 45, FeraMAX Pd Powder 15, Gelclair, Inofolic, Proktis-M, RepaGyn, and Tibella. Combogesic is for the short-term management of mild to moderate acute pain and the reduction of fever in adults. Cathejell combines sterile gel and 2% lidocaine jelly in a collapsible syringe that is ready to use. FeraMAX Pd Therapeutic 150 is an oral hematinic that helps the body form red blood cells and is indicated for the treatment of iron deficiency anemia.


TSXV:RX - Post by User

Bullboard Posts
Post by bthoughtson Sep 25, 2014 11:09pm
199 Views
Post# 22972237

Biosyent Inc - Insider Selling

Biosyent Inc - Insider Selling

Source: INK Research September 24, 2014 

Sep 18/14 Larson, Douglas Robert Direct Ownership Public market sale Common Shares 12.29 -1,000 -5.6% 17,000

Sep 17/14 Wakefield, Milt Direct Ownership Public market sale Common Shares 11.51 - 11.53 -2,000 -3.1% 62,500

Sep 15/14 Larson, Douglas Robert Direct Ownership Public market sale Common Shares 11.65 - 11.70 -2,000 -10.0% 18,000

I think the above may have been the catalyst that triggered the recent drop. Insider selling, triggered panic selling, and then more panic selling. Also the recent overall TSX market drop may have played a factor as well. The P/E Ratio of RX is also pretty high at about P/E 58.44 according to Google Finance. I'm not too familar with Canadian phaurameticals, what is the industries average P/E? Do they usually run this high of a P/E?

Bullboard Posts